WillItSurvive
No grouping · United States

BlossomHill Therapeutics, Inc.

Clinical-stage oncology biotech filing for Nasdaq IPO, no approved drugs yet.

Losing its protection
Assessed 29 July 2026 · Evidence as of 29 July 2026
The structural protection is eroding.
On the recordSince 29 July 2026 · Checkable from Q4 2026 · Every call on the record Checkpoint: FDA End-of-Phase-1 meeting on BH-30643 for accelerated approval path in C797S resistance
The call

BlossomHill is racing to prove BH-30643 in a resistance niche while Black Diamond runs a phase ahead and AstraZeneca and J&J hold the broader EGFR market.

BlossomHill Therapeutics is trying to develop new cancer medicines, particularly drugs targeting specific genetic mutations in lung cancer where bigger companies like AstraZeneca and Johnson & Johnson already sell approved treatments. The company has raised a lot of money and its founder has successfully brought three drugs to market before, but BlossomHill has not yet sold any drugs of its own and burns through roughly $71 million per year. A rival company called Black Diamond is already further along testing a similar type of drug in patients, which makes BlossomHill's job harder; the make-or-break moment comes when BlossomHill shares early patient data on its main drug candidate in late 2026, which will show whether the company's approach actually works better than what already exists.

Why
01
AI pressure: None apparent. AI drug-design tools could speed rivals' discovery timelines, but no AI product competes directly with BlossomHill's EGFR or KRAS programs. Could AI do the core job? Unlikely.
02
Bigger players: AstraZeneca (Tagrisso) and J&J (Rybrevant plus Lazcluze). AstraZeneca and J&J already own first-line EGFR-mutant NSCLC with approved combos, leaving BlossomHill only the smaller resistance-mutation niche. Could a giant copy it? Yes, easily.
03
What protects it. Founders designed three FDA-approved cancer drugs and sold a prior company to Bristol Myers Squibb for $4.1B, backing specific molecule IP in C797S resistance.
What would change this call
Black Diamond Therapeutics reports silevertinib Phase 2 data in EGFR C797S NSCLC before Q4 2026. Would show a rival reaching the same resistance niche and regulatory milestone first.
BlossomHill's Q4 2026 FDA End-of-Phase-1 meeting outcome on BH-30643 is publicly disclosed. Confirms whether an accelerated approval path is viable or the program slips.
J&J discloses Rybrevant+Lazcluze sales or share gains specifically in EGFR-resistant segments through 2026-2027. Shows incumbents expanding into the resistance population BlossomHill is targeting.
Key numbers
  • $257M raised cumulative across Series B and extension (2025-12-10)
  • $71.09M net loss, $0 revenue trailing 12 months (2026-07-16)
  • 63 employees at IPO filing (2026-07-16)
Named risks
  • Pre-revenue with $71 million annual burn and no approved product as of July 2026. Severity: high
  • Black Diamond already Phase 2 ahead in the same C797S EGFR resistance niche. Severity: high
  • Crowded 2026 biotech IPO class of 18-plus companies competing for the same investor pool. Severity: medium
  • Historical Phase 1/2 oncology to approval probability is only around 10 to 15 percent. Severity: high
  • Prior C797S-targeting programs from Blueprint Medicines failed on futility grounds in 2024. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Black Diamond Therapeuticslosing toSilevertinib already in Phase 2 with 42% ORR data for EGFR C797S niche as of May 21, 2026, ahead of BlossomHill's Phase 1/2 BH-30643
Revolution Medicineslosing toDaraxonrasib in Phase 3 with FDA NDA under priority review as of July 27, 2026, versus BlossomHill's preclinical pan-KRAS asset
Johnson and Johnsonlosing toRybrevant plus Lazcluze combo sales doubled to $734 million in 2025, entrenched in same EGFR-mutant NSCLC space
AstraZenecalosing toTagrisso remains first-line EGFR standard backed by $58.7 billion FY2025 revenue, dwarfing BlossomHill's resources
Blueprint Medicinesgaining onBlueprint's rival C797S-targeting drugs tigozertinib and BLU-701 were discontinued for futility in January 2024
Questions people ask
Is BlossomHill Therapeutics profitable?
No. BlossomHill is pre-revenue, reporting $0.0 million in trailing 12-month revenue and a net loss of approximately $71.09 million as of its July 16, 2026 IPO filing. It has no approved products; all value depends on future clinical trial outcomes for its pipeline drugs.
When is BlossomHill Therapeutics going public?
BlossomHill filed a public S-1 with the SEC on July 17, 2026, seeking to raise up to $100 million on Nasdaq under ticker BLSM, after confidentially filing in April 2026. Pricing and share count had not been set as of the filing date.
Who is BlossomHill Therapeutics' biggest competitor?
Black Diamond Therapeutics is the closest direct rival, with its drug silevertinib already in Phase 2 for the same EGFR C797S resistance population BlossomHill's BH-30643 targets, posting 42% ORR and 15.2-month mPFS data at ASCO on May 21, 2026, one trial phase ahead of BlossomHill.
What is BlossomHill Therapeutics' lead drug and when is the next milestone?
BH-30643, a non-covalent EGFR inhibitor for EGFR-mutant NSCLC, is in the Phase 1/2 SOLARA trial targeting the C797S resistance population. Its next milestone is an FDA End-of-Phase-1 meeting targeting an accelerated approval pathway, expected Q4 2026.
Who founded BlossomHill Therapeutics and what is their track record?
Co-founded in June 2020 by J. Jean Cui, Ph.D. and Y. Peter Li, Ph.D., who previously co-founded Turning Point Therapeutics, sold to Bristol Myers Squibb for about $4.1 billion in June 2022. Cui designed three FDA-approved oncology drugs: crizotinib, lorlatinib, and repotrectinib.
How much money has BlossomHill Therapeutics raised before its IPO?
BlossomHill has raised $257 million cumulatively as of a December 10, 2025 $84 million Series B extension led by Janus Henderson Investors, Brahma Capital, and BioTrack Capital, following a $100 million Series B closed February 29, 2024 led by Colt Ventures.
Timeline
  • 2026-07-21BlossomHill discloses BH-501284 pan-KRAS IND submission planned for Q1 2027
  • 2026-07-17BlossomHill files public S-1 with SEC for Nasdaq IPO under ticker BLSM
  • 2026-07-16Renaissance Capital lists BlossomHill at 63 employees ahead of IPO
  • 2026-05-21Black Diamond Therapeutics presents positive silevertinib Phase 2 EGFR data at ASCO
  • 2026-05-20BlossomHill appoints Sheila Gujrathi and John Schmid to board
  • 2026-04-22BlossomHill presents first pan-KRAS BH-501284 preclinical data at AACR 2026
  • 2026-04-01BlossomHill confidentially files for IPO with SEC
  • 2025-12-10BlossomHill closes $84 million Series B extension, total raised reaches $257 million
  • 2024-02-29BlossomHill closes $100 million Series B financing led by Colt Ventures
  • 2022-06-01Bristol Myers Squibb acquires founders' prior company Turning Point Therapeutics for $4.1 billion
Revision history
29 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
American Airlines GroupSafe Superintelligence Inc.Wayfair
More companies losing its protection →
Sources